Perceptive Advisors Llc Buys 37,712 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc bought 37,712 shares of Aldeyra Therapeutics stock in a transaction dated Friday, April 5th. The stock was acquired at an average cost of $4.74 per share, with a total value of $178,754.88. Following the completion of the acquisition, the insider now owns 9,275,851 shares of the company's stock, valued at $43,967,533.74. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

• On Wednesday, April 3rd, Perceptive Advisors Llc acquired 309,847 shares of Aldeyra Therapeutics stock. The stock was acquired at an average price of $4.09 per share, with a total value of $1,267,274.23.
• On Monday, April 1st, Perceptive Advisors Llc bought 8,374 shares of Aldeyra Therapeutics stock. The shares were acquired at an average price of $3.25 per share, for a total transaction of $27,215.50.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX traded down $0.34 during trading on Monday, hitting $4.38. 1,033,645 shares of the company's stock traded hands, compared to its average volume of 586,043. The stock has a market capitalization of $257.98 million, a price-to-earnings ratio of -6.84 and a beta of 1.51. Aldeyra Therapeutics, Inc has a 12-month low of $1.42 and a 12-month high of $11.97. The business has a 50 day moving average of $3.42 and a 200-day moving average of $3.36.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.13. On average, analysts expect that Aldeyra Therapeutics, Inc will post -0.14 EPS for the current year.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several institutional investors have recently made changes to their positions in ALDX. Los Angeles Capital Management LLC boosted its position in shares of Aldeyra Therapeutics by 240.9% in the first quarter. Los Angeles Capital Management LLC now owns 380,773 shares of the biotechnology company's stock valued at $1,245,000 after acquiring an additional 269,061 shares during the period. Vanguard Group Inc. lifted its stake in Aldeyra Therapeutics by 23.2% in the 4th quarter. Vanguard Group Inc. now owns 3,927,597 shares of the biotechnology company's stock worth $13,786,000 after purchasing an additional 740,177 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Aldeyra Therapeutics by 12.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,827 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 4,935 shares during the period. GSA Capital Partners LLP grew its position in shares of Aldeyra Therapeutics by 1,005.6% during the 4th quarter. GSA Capital Partners LLP now owns 168,763 shares of the biotechnology company's stock valued at $592,000 after purchasing an additional 153,499 shares in the last quarter. Finally, Palo Alto Investors LP increased its holdings in shares of Aldeyra Therapeutics by 40.2% in the fourth quarter. Palo Alto Investors LP now owns 225,465 shares of the biotechnology company's stock worth $791,000 after purchasing an additional 64,665 shares during the period. Hedge funds and other institutional investors own 59.71% of the company's stock.

Analysts Set New Price Targets

ALDX has been the subject of several research reports. Oppenheimer upgraded shares of Aldeyra Therapeutics from a "market perform" rating to an "outperform" rating and set a $10.00 price target for the company in a research report on Wednesday, April 3rd. StockNews.com upgraded shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, January 29th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a report on Tuesday, April 2nd.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.